Lumenis Ltd. said it plans to sell 6.25 million shares at $15 to $17 apiece in its upcoming initial public offering.
That would bring in between $93.8 million and $106.3 million for the Israeli medical laser maker, which announced the IPO late last year.
The offering will include a 30-day over-allotment of another 937,500 shares, according to a press release. If exercised, that would add $14.1 million to $15.9 million to the Lumenis IPO. The stock will trade on the NASDAQ exchange under the LMNS symbol.
When Yokneam, Israel-based Lumenis announced the IPO in December 2013, it said it hoped to bring in as much as $115 million.
In November 2013, Lumenis won clearance in the U.S. and Japan for its Array LaserLink pattern scanning device for multi-spot retinal laser treatment. Earlier in 2013, the FDA slapped the company with a Class I recall of its VersaCut morcellator.